Patent US4282201A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4282201A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical comprising drug and polymer

Assignee: Alza Corp
•
Filing: 1979-11-05
•
Granted: 1981-08-04
•
Expires: 1999-11-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention concerns polymers of the general formula: ##STR1## wherein R is a multivalent hydrocarbon radical and Het is a 5 to 8 membered heterocyclic system having a nitrogen, oxygen or sulfur hetero atom. The polymers are useful for making articles of manufacture and as coating for delivering beneficial agents.

Inventors

  • 👤 Nam S. Choi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 11:38
CPC Classifications
C; C08; C08G; C08G85/00; A; A01; A01N; A01N25/00; A01N25/08; A01N25/10; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; A61L; A61L9/00; A61L9/015; A61L9/04; A61L9/042; C05; C05G; C05G5/00; C05G5/30; C05G5/37; C08G65/00; C08G65/34; C08G73/00; C08G73/06; C08G73/0605; C08G73/0611; C08G73/0622; C08G73/0627; C08L; C08L2203/00; C08L2203/02

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 401 words
A drug delivery device for the administration of drug to a biological drug receptive environment, wherein the device comprises: (I) a shaped matrix sized, structured and adapted for administering drug to the environment and formed of a drug release rate controlling pharmaceutically acceptable material, which material comprises a polymer of the formula: ##STR9## wherein R is a member selected from the group consisting of divalent, trivalent, and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkenyl of 2 to 7 carbons, an alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons, and alkylene of 2 to 10 carbons; cycloalkenylene of 4 to 7 carbons, cycloalkylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; arylene of 6 to 16 carbons; arylene of 6 to 16 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; and Het is a heterocyclic five to eight membered ring comprising: (1) a carbon atom bivalently bonded to the oxygen atoms of the polymer; (2) a hetero ring atom adjacent to the carbon atom of the polymer chain, said hetero atom selected from the group consisting of nitrogen, sulfur and oxygen; and (3) with the remainder of the ring independently selected from (a) and (b) wherein (a) is an alkylene bridge of 2 to 5 carbons substituted with a ring atom selected from the group consisting of nitrogen and sulfur; and (b) is an alkylene bridge of 3 to 6 carbons when said hetero atom adjacent to the carbon atom of the polymer chain is a hetero ring atom selected from the group consisting of nitrogen and sulfur; and n is greater than 10; (II) a drug selected from the group consisting of locally and systemically acting physiologically and pharmaceutically acceptable drug present in the matrix; and (III) wherein the device when in operation administers a therapeutically effective amount of drug to the environment over a period of time.
Claim 2
Dependent Claim 401 words
A drug delivery device for the administration of drug to a biological drug receptive environment, wherein the device comprises: (I) a shaped matrix sized, structured and adapted for administering drug to the environment and formed of a drug release rate controlling pharmaceutically acceptable material, which material comprises a polymer of the formula: ##STR9## wherein R is a member selected from the group consisting of divalent, trivalent, and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkenyl of 2 to 7 carbons, an alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons, and alkylene of 2 to 10 carbons; cycloalkenylene of 4 to 7 carbons, cycloalkylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; arylene of 6 to 16 carbons; arylene of 6 to 16 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; and Het is a heterocyclic five to eight membered ring comprising: (1) a carbon atom bivalently bonded to the oxygen atoms of the polymer; (2) a hetero ring atom adjacent to the carbon atom of the polymer chain, said hetero atom selected from the group consisting of nitrogen, sulfur and oxygen; and (3) with the remainder of the ring independently selected from (a) and (b) wherein (a) is an alkylene bridge of 2 to 5 carbons substituted with a ring atom selected from the group consisting of nitrogen and sulfur; and (b) is an alkylene bridge of 3 to 6 carbons when said hetero atom adjacent to the carbon atom of the polymer chain is a hetero ring atom selected from the group consisting of nitrogen and sulfur; and n is greater than 10; (II) a drug selected from the group consisting of locally and systemically acting physiologically and pharmaceutically acceptable drug present in the matrix; and (III) wherein the device when in operation administers a therapeutically effective amount of drug to the environment over a period of time.
Claim 3
Dependent Claim 21 words
The drug delivery device for the administration of drug according to claim 1 wherein the drug receptive environment is an animal.
Claim 4
Dependent Claim 33 words
The drug delivery device for the administration of drug according to claim 1 wherein the drug receptive environment is a human and the matrix contains from 0.01% to 40% by weight of drug.
Claim 5
Dependent Claim 43 words
The drug delivery device for the administration of drug according to claim 1, wherein the remainder of the heterocyclic ring comprises an alkylene bridge of 3 to 6 carbons substituted with an extralinear member selected from the group consisting of mercapto and amino.
Claim 6
Dependent Claim 59 words
The drug delivery device for the administration of drug according to claim 1, wherein the remainder of the heterocyclic ring is a dialkylene bridge of 2 to 5 carbon atoms having a linear ether between alkylene group of the bridge when the hetero atom pendant from the polymer backbone is selected from the group consisting of nitrogen and sulfur.

References Cited (Backward Citations)

US4093709A Cited
US4131648A Cited
US4138344A Cited
US4180646A Cited
US4066747A Cited
US4119579A Cited
US4136252A Cited
US4155740A Cited
US4186185A Cited
US4070347A Cited
US4155992A Cited
US4122158A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-08-03 1985-02-02 1985-08-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-08-03 1989-02-02 1989-08-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-08-03 1993-02-02 1993-08-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag